(Q37710367)

22 August 2017

1 reference

title

mTOR signaling and drug development in cancer (English)

1 reference

22 August 2017

Janet Dancey

1

1 reference

PubMed ID

20234352

22 August 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

209-219

1 reference

22 August 2017

4

1 reference

Optimal targeting of the mTORC1 kinase in human cancer

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Mammalian target of rapamycin as a therapeutic target in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Targeting phosphoinositide 3-kinase: moving towards therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A complex interplay between Akt, TSC2 and the two mTOR complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Lost in translation: dysregulation of cap-dependent translation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

The TOR pathway: a target for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Current development of mTOR inhibitors as anticancer agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Targeting mTOR in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Rapamycin and mTOR kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Targeting mTOR with rapamycin: one dose does not fit all

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase I study of everolimus in pediatric patients with refractory solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Pharmacokinetics of mycophenolate mofetil and sirolimus in children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Clinical pharmacokinetics of everolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

mTOR inhibitors: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Malignancy in kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

The role of mTOR inhibitors in the management of posttransplant malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Therapeutic targeting of mTOR in tuberous sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Rapamycin treatment for a child with germline PTEN mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Intraperitoneal chemotherapy for ovarian cancer: overview and perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.21

Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells

31 March 2020

1 reference

12 December 2020

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

1 reference

12 December 2020

Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

1 reference

12 December 2020

Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin

1 reference

12 December 2020

10.1038/NRCLINONC.2010.21

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20234352